The Australian government is moving to block a $387.2m takeover deal of Mayne Pharma by US company Cosette Pharmaceuticals, citing a “national security” need to protect “critical medical supply chains.”
Mayne Pharma’s business, which focuses on therapeutic areas like women’s health, dermatology, pain, and infectious diseases, is mainly in the

